Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era

Philadelphia chromosome (Ph) is detected in approximately 20 to 30 percent of adult acute lymphoblastic leukemia (ALL) [1 –3]. The long-term outcome on conventional chemotherapy alone is dismal even in patients who achieve complete remission, because of a high relapse rate. Therefore, allogenic hematopoietic stem cell transplantation (HSCT) is the standard consolidation therapy, when feasible [4,5]. Over the last dec ade, tyrosine kinase inhibitor (TKI) has dramatically improved the survival outcome of Ph+ ALL [6–12].

Source: Biology of Blood and Marrow Transplantation - June 13, 2018 Category: Hematology Authors: Yu Akahoshi, Shuichi Mizuta, Hiroaki Shimizu, Naoyuki Uchida, Takahiro Fukuda, Heiwa Kanamori, Makoto Onizuka, Yukiyasu Ozawa, Kazuteru Ohashi, Shuichi Ohta, Tetsuya Eto, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako Source Type: research